Cubist sales force seen as potential boon for Merck intestinal drug

By Ransdell Pierson (Reuters) - In its planned purchase of antibiotics maker Cubist Pharmaceuticals Inc, Merck & Co will gain a sales force well placed to propel its own experimental drug for an intestinal bug, C. difficile, that is a scourge among hospital patients. Merck announced on Monday an agreement to buy Cubist for $8.4 billion, with a focus on Cubist's drugs that address the growing threat of bacteria that are resistant to conventional antibiotics. As many as 14,000 Americans die each year from C. difficile infections, which are spread by spores in hospitals. ...



via Health News Headlines - Yahoo News http://ift.tt/12pCIZz